Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

Myelosuppression Clinical Trial

Official title:

Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05442177
• Other study ID #: REC104-12
• Status: Completed
• Start date: July 1, 2015
• Est. completion date: June 30, 2016

Study information

• Verified date: June 2022
• Source: Taichung Tzu Chi Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We conducted an observational study to investigate the effectiveness and safety of Integrated Chinese Medicine With Western Medicine for bone marrow suppression induced by chemotherapy in patients with cancer. The TCM constitution and pulse diagnosis was also observed in the study.

Description:

Patients with cancer under chemotherapy and integrated Western and Chinese medicine were enrolled in this observational study. The assessment of radial pressure pulse (RPP) was performed before and after chemotherapy. The correlation between the spectral energy (SE0-10 Hz, SE10-50 Hz, and SE13-50 Hz) of the RPP at six diagnosis positions and the blood cell counts before and after chemotherapy were analyzed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: June 30, 2016
• Est. primary completion date: June 30, 2016
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with cancer diagnosed through pathological histology

• Patients with cancer under chemotherapy and Integrated Chinese Medicine With Western Medicine

• Patients with an Eastern Cooperative Oncology Group Performance score of 0-2

• Patients having normal liver and kidney functions and electrocardiography and eligible for chemotherapy with normal bone marrow hematopoietic function

• Patients who were voluntarily involved in this study

Exclusion Criteria:

• Cases that did not meet the inclusion criteria

• Patients who could not cooperate with pulse diagnosis

• Patients with underlying diseases such as chronic obstructive pulmonary disease, cardiac failure, chronic renal failure, cirrhosis, etc.

• Patients with severe infection

• Patients with severe cachexia

Related Conditions & MeSH terms

• Myelosuppression

Intervention

Procedure:
• Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Taichung Tzu Chi Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Chemotherapy-induced Hematologic Toxicity	the blood cell count before and after chemotherapy was collected for measurement of severity of myelosuppression	one month